Joseph B. Horn
President and CEO
Joseph Horn joined Colibri Heart Valve, LLC in 2011 as President and CEO. Joe has spent the last thirty years in the medical industry, ranging from orthopedics to cardiovascular applications. He is a successful medical device entrepreneur and executive and has focused on cardiology for the last 25 years. Prior to joining Colibri, he last served as President of Global Therapeutics, a Cook Group company. He co-founded Global Therapeutics in 1990 where his responsibilities as President and CEO ranged from development of vascular products to approval and sales in over 40 countries. Global Therapeutics was acquired by COOK in 1998.
Vice President, Corporate Development
Eric Schauble joined Colibri Heart Valve, LLC in June 2011 as Vice President, Corporate Development. Eric brings over eleven years of experience in the biotech/ pharmaceutical and strategic consulting industries with a strong track record of success. Prior to joining Colibri, he served in the position of Vice President, Corporate Development for Accera, Inc., a privately held biotechnology company where he successfully developed and executed the company’s strategic corporate and business development strategy. Prior to joining Accera, Eric has served in various corporate/business development and commercial roles, most notably as the Director of Market Research for Myogen, Inc. which was acquired by Gilead Sciences in 2006 for $2.5 billion. He received his B.S. in Pharmacology from the University of California at Santa Barbara and his M.S. in Biological Sciences, with an emphasis on Cardiovascular Physiology, from Stanford University.
William (Bill) Jackson
Vice President, Regulatory, Clinical, and Compliance
William (Bill) Jackson has over 30 years of regulatory, clinical, and compliance experience. Most recently, Bill has served as president of W.F. Jackson Associates, Ltd., a successful practice he founded to provide regulatory, quality and clinical consulting services to domestic and international medical device companies. Previous to this, Bill held senior management positions at a variety of medical device companies including Intermedics, Neuromed, Genetic Labs (porcine), St. Jude Medical, TranS1, MiMedix, and Optovue. During his tenure at St. Jude, Bill worked on the committee that created the first two directives that outlined the essential requirements and classification rules for the assessment of medical devices (MDD) and active implantable medical devices (AIMD). Before joining industry, Bill conducted cardiology research and developed clinical trial protocols for the department of cardiology at the University of North Dakota, School of Medicine. During his career, Bill has prepared and lead over 400 regulatory submissions to more than 75 countries (European Economic Area, Pan Pacific countries, and the Americas). Bill received a Bachelor of Arts in zoology and minors in chemistry and physiological psychology from Concordia College and a Master of Business Administration from the University of Minnesota (Moorhead).
Thomas P. Reagan
Corporate and Financial Advisor and Board of Director
Thomas Reagan joined Colibri Heart Valve, LLC as a Board of Director in January 2013. Mr. Reagan is Chairman of the Board and CEO of Reagan Partnership where he oversees the investing and operating activities in the real estate development, real estate franchising, and asset management industries. Previously he was a managing director of J.P. Morgan where he spent approximately 20 years overseeing the European and Asian Equity and Equity Derivatives business and the Private Equity investing arm. He was one of four executives appointed by the CEO to merge the global investment banking activities of J.P. Morgan with Chase in 2000/2001. He earned his B.A. in Economics from the University of Colorado and his M.S. in Mineral Economics from the Colorado School of Mines.